Phase II Study to Evaluate the Efficacy of Trilogy Stereotactic Radiosurgery for Pancreatic Cancer

This study will assess the efficacy of treating locally advanced pancreatic cancer using Stereotactic Body Radiotherapy (using Trilogy) and Gemcitabine

Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.

Investigator(s):

Intervention(s):

  • drug : Gemcitabine
  • radiation : Stereotactic Body Radiotherapy

Phase: Phase 2

Eligibility

Ages Eligible For Study:

18 Years - 90 Years

Inclusion Criteria

- Pancreatic tumors not to exceed 10 cm in greatest axial dimension - Histologically confirmed malignancies of the pancreas - Unresectable by CT criteria or exploratory laparotomy or laparoscopy - Patients with metastatic disease may be treated if they are symptomatic from the primary tumor - Performance status of 0, 1, or 2 - No chemotherapy two weeks prior or two weeks following radiosurgery

External Links

Explore related trials

Contact information

Primary Contact:

Jeff Kim 6504987703

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: